Special Issue "COVID-19 Vaccines in the Context of Patients with Autoimmune Inflammatory Diseases"
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 22817
Interests: autoimmune inflammatory rheumatic diseases (AIRDs); women’s health in patients with AIRDs; inflammation and hyperinflammation; COVID-19 vaccines
Interests: autoimmune inflammatory rheumatic diseases; COVID-19 vaccines; inflammation and hyperinflammation
Interests: pneumonia; sepsis; vaccines; antibiotic resistance
Special Issues, Collections and Topics in MDPI journals
The COVID-19 pandemic, at this stage, has almost resulted in 4 million deaths globally.
A growing body evidence is emerging on the epidemiology and pathophysiology of COVID-19. There has been a considerable amount of concern amongst physicians and scientists about patients with underlying autoimmune inflammatory diseases in relation to whether this particular patient group is more susceptible to becoming infected with COVID-19; whether they have more severe COVID-19-related disease morbidity and mortality; whether the currently available vaccinations against COVID-19 are efficient.
This Special Issue will focus on COVID-19 vaccines in the context of patients with autoimmune inflammatory diseases in a broad context.
Dr. Karen Schreiber
Prof. Dr. Oliver Hendricks
Prof. Dr. Mathias Pletz
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- COVID-19 vaccines
- autoimmune diseases